-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CAR-T is to directly inject or transplant biologically engineered or normal human cells into the patient's body, allowing the newly imported cells to replace the damaged cells, thus having a more powerful immune killing function.
In order to achieve the therapeutic effect
.
CAR-T drugs are drugs produced based on the above principles and are a special immunotherapy
.
At present, in cancer treatment, CAR-T drugs are very popular and concerned
.
Recently, CAR-T drug Akirensai injection (trade name Yikaida) has entered the public eye
.
It is reported that China’s first approved CAR-T drug Akirensai injection (Yikaida) developed by Fosun Kate Biotechnology Co.
, Ltd.
was approved for marketing in June this year.
It is said that a single injection can make cancer cells.
Disappear
.
Akirensai injection is a customized live-cell medicine that modifies the patient's autologous T cells through genetic engineering, expresses targeted tumor antigen molecules, and activates T cells to mediate and kill tumor cells
.
According to Health Times, on August 26, the first case of CAR-T-treated lymphoma patient in China was discharged from Shanghai Ruijin Hospital.
The patient's cancer cells were cleared within 2 months
.
According to the industry, although CAR-T drugs are expensive, such as a single dose of Akirensai injection reaching 1.
2 million yuan, the prospects of the CAR-T cell therapy market cannot be underestimated
.
According to consulting firm Frost & Sullivan, the global CAR-T cell therapy market is estimated to be 700 million U.
S.
dollars in 2019, and it will increase to 6.
6 billion U.
S.
dollars by 2024.
By 2030, this market may reach 21.
8 billion U.
S.
dollars
.
In China, with the increase in cancer patient groups, the increase in qualified hospitals, and favorable policies and capital investment, the market size of CAR-T cell therapy has a compound annual growth rate of 45%, and it may increase to 289 by 2030.
100 million yuan
.
Driven by the vast market, the enthusiasm for research and development of pharmaceutical companies is also increasing
.
According to statistics, China has 475 researches on CAR-T
.
Up to now, there are 358 ongoing CAR-T clinical trials in China, including the drug name Junuo, Legend Biology, Keji Pharmaceutical, etc.
.
Among them, Legend Bio has 7 CAR-T cell therapy products in the clinical stage, and Keji Pharmaceutical has 5 CAR-T cell therapy products in the clinical stage
.
In addition, it’s worth noting that WuXi Junuo issued an announcement on September 3 that its CAR-T product targeting CD19, Ruiji Oransay injection, was approved for marketing
.
The drug can be used to treat relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after second-line or above systemic treatment
.
It is reported that WuXi Giant Nuo has a variety of CAR-T cell therapy products, most of which are still in the pre-clinical stage.
The news of the approval of Ruiji Orenza injection for the market soon spread to the secondary market
.
On the first trading day after the announcement (September 6), WuXi Junuo's stock price rose 28.
09%.
As of the close of September 9th, the company's stock price remained above HK$20 per share
.
According to the industry, cellular immunotherapy represented by CAR-T is a major breakthrough in the treatment of hematological tumors in recent years, bringing curative effects and hope of cure for patients with relapsed and refractory hematological tumors
.
However, as one of the current high-end methods of cancer treatment, the production cost of CAR-T therapy is much more complicated than traditional treatment methods.
The use process includes drawing patient blood, separating T cells in the blood, activating T cell activity, and expanding effective T cells.
The cells are released and freeze-dried until finally implanted in the patient's body.
The whole process is very complicated and the cultivation cost is very high
.
This also makes CAR-T expensive to discourage patients
.
Regarding how to increase the availability of products, Fosun Pharma stated in response to investors’ questions on September 14 that while controlling the quality of medicines and ensuring the accuracy and speed of manufacturing and delivery, the joint venture Fosun Kate is also Actively increase the availability of the product to benefit more patients by expanding indications, continuously optimizing costs, and exploring diversified payment methods such as commercial insurance
.
In order to achieve the therapeutic effect
.
CAR-T drugs are drugs produced based on the above principles and are a special immunotherapy
.
At present, in cancer treatment, CAR-T drugs are very popular and concerned
.
Recently, CAR-T drug Akirensai injection (trade name Yikaida) has entered the public eye
.
It is reported that China’s first approved CAR-T drug Akirensai injection (Yikaida) developed by Fosun Kate Biotechnology Co.
, Ltd.
was approved for marketing in June this year.
It is said that a single injection can make cancer cells.
Disappear
.
Akirensai injection is a customized live-cell medicine that modifies the patient's autologous T cells through genetic engineering, expresses targeted tumor antigen molecules, and activates T cells to mediate and kill tumor cells
.
According to Health Times, on August 26, the first case of CAR-T-treated lymphoma patient in China was discharged from Shanghai Ruijin Hospital.
The patient's cancer cells were cleared within 2 months
.
According to the industry, although CAR-T drugs are expensive, such as a single dose of Akirensai injection reaching 1.
2 million yuan, the prospects of the CAR-T cell therapy market cannot be underestimated
.
According to consulting firm Frost & Sullivan, the global CAR-T cell therapy market is estimated to be 700 million U.
S.
dollars in 2019, and it will increase to 6.
6 billion U.
S.
dollars by 2024.
By 2030, this market may reach 21.
8 billion U.
S.
dollars
.
In China, with the increase in cancer patient groups, the increase in qualified hospitals, and favorable policies and capital investment, the market size of CAR-T cell therapy has a compound annual growth rate of 45%, and it may increase to 289 by 2030.
100 million yuan
.
Driven by the vast market, the enthusiasm for research and development of pharmaceutical companies is also increasing
.
According to statistics, China has 475 researches on CAR-T
.
Up to now, there are 358 ongoing CAR-T clinical trials in China, including the drug name Junuo, Legend Biology, Keji Pharmaceutical, etc.
.
Among them, Legend Bio has 7 CAR-T cell therapy products in the clinical stage, and Keji Pharmaceutical has 5 CAR-T cell therapy products in the clinical stage
.
In addition, it’s worth noting that WuXi Junuo issued an announcement on September 3 that its CAR-T product targeting CD19, Ruiji Oransay injection, was approved for marketing
.
The drug can be used to treat relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after second-line or above systemic treatment
.
It is reported that WuXi Giant Nuo has a variety of CAR-T cell therapy products, most of which are still in the pre-clinical stage.
The news of the approval of Ruiji Orenza injection for the market soon spread to the secondary market
.
On the first trading day after the announcement (September 6), WuXi Junuo's stock price rose 28.
09%.
As of the close of September 9th, the company's stock price remained above HK$20 per share
.
According to the industry, cellular immunotherapy represented by CAR-T is a major breakthrough in the treatment of hematological tumors in recent years, bringing curative effects and hope of cure for patients with relapsed and refractory hematological tumors
.
However, as one of the current high-end methods of cancer treatment, the production cost of CAR-T therapy is much more complicated than traditional treatment methods.
The use process includes drawing patient blood, separating T cells in the blood, activating T cell activity, and expanding effective T cells.
The cells are released and freeze-dried until finally implanted in the patient's body.
The whole process is very complicated and the cultivation cost is very high
.
This also makes CAR-T expensive to discourage patients
.
Regarding how to increase the availability of products, Fosun Pharma stated in response to investors’ questions on September 14 that while controlling the quality of medicines and ensuring the accuracy and speed of manufacturing and delivery, the joint venture Fosun Kate is also Actively increase the availability of the product to benefit more patients by expanding indications, continuously optimizing costs, and exploring diversified payment methods such as commercial insurance
.
